DC ChemicalsChemicals for Life Science
sales@dcchemicals.com

DC68150 · Updated 24 October 2026

Lipid A10 (CSS-A10)
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

Literature-reported formulation composition

Componentmol%Role
CSS-A1035Ionizable lipid
Cholesterol47.5Sterol
C14PEG20002.5PEG lipid
DOTAP15Additional lipid components
Reported total100Source values retained
Formulation calculator unavailable. CSS-A10 is verified as C52H100N4O6 with a calculated average MW of 877.39 g/mol. The exact molecular-weight specifications for C14PEG2000 and DOTAP remain unverified in this formulation record. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Not reported in the cited article
mRNA diluted in 25 mM sodium acetate; lipid phase prepared in ethanol; final LNP dialyzed into sterile PBS. The rhesus formulation was cryopreserved in 10% sucrose/PBS before shipment and dosing.
Membrane-anchored NanoLuc luciferase mRNA (aNLuc mRNA)
Intravenous injection
0.25 or 0.4 mg mRNA/kg, single dose
Young rhesus monkeys (Macaca mulatta), 7-8 months old; n=4 at 0.25 mg/kg and n=3 at 0.4 mg/kg; one untreated control; tissues collected approximately 24 h after dosing
Aqueous nucleic-acid and ethanol lipid phases were mixed using a NanoAssemblr Spark or Ignite at a 3:1 aqueous:lipid-phase flow-rate ratio, dialyzed against PBS overnight at 4 °C and sterile-filtered. The NHP batch was frozen, shipped, thawed and tested before dosing.

Literature-reported performance for the cited formulation

Literature-reported80 nmLNP67 characterizationMain article Figure 2d
Literature-reported86.7%LNP67 characterizationMain article Figure 2b
Literature-reported-2.58 mVLNP67 characterizationMain article Figure 2e
Literature-reported6.4TNS fluorescence assayMain article Figure 2f and Methods
Literature-reportedDose-dependent aNLuc expression was detected in CD34+ bone-marrow cells; expression in CD34+ cells was similar to liver-cell expression at both tested doses.Approximately 24 h · Untreated control and liver-cell suspensionsMain article Figure 4c-g and accompanying text

Additional reported findings

Ligand-free bone-marrow delivery

LNP67 was selected from an in vivo screen of 105 quality-controlled formulations and showed the most favorable bone-marrow-versus-liver delivery profile among the individually tested lead formulations.

Mouse screening and individual confirmation; no antibody or other targeting ligand was attached to LNP67 · Main article Figures 1g and 2a
Mouse HSC/HSPC dose response

After intravenous administration, LNP67 produced dose-dependent reporter expression across eight bone-marrow HSC/HSPC subtypes, including reporter-positive multipotent progenitors.

C57BL/6J mice; aVHH mRNA; 0.5, 1.0 and 1.5 mg/kg; 16 h · Main article Figure 2i
Preliminary rhesus tolerability observation

The authors reported no adverse findings or serum-cytokine differences versus the untreated control at the tested doses without anti-inflammatory pretreatment.

Seven treated young rhesus monkeys and one untreated control; 23 serum cytokines; approximately 24 h. This small study is not a formal toxicology package. · Main article Figure 4h and Discussion
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetKim H, Zenhausern R, Gentry K, et al. Lipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys. Nature Biotechnology. Published online 16 November 2024. DOI: 10.1038/s41587-024-02470-2
The Nature Biotechnology article reports LNP67 composition by component class, physicochemical properties and mouse/rhesus performance, while calling the ionizable lipid proprietary. WO2025217298A1, claiming priority to US 63/632,354 cited by the paper, identifies LNP67 as CSS-A10/cholesterol/C14PEG2000/DOTAP at 35:47.5:2.5:15 mol%.

Primary article · LNP67 patent disclosure